IO Biotech Exceeds Q2 2024 EPS Expectations
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
- Latest
- Trending
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Discover how Novo Nordisk, Moderna, and Regeneron are poised for growth amidst market volatility with innovative biotech solutions.
Woodridge Police use VR for de-escalation, marking Illinois' first such use.
Discover promising biotech stocks with expert insights on market trends and innovative drugmakers worth your investment.
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Roivant reports strong clinical progress, with significant Phase 3 study completions, revenue growth, and financial strength.
Southern Miss advances biomaterials research for immune disease treatment with a $2.5M collaboration, boosting Mississippi's biotech.
Explore promising biotech stocks like Vertex, Pfizer, and Merck, ready to innovate and grow in the evolving healthcare landscape.
Supernus Pharmaceuticals sees a 24% YoY revenue increase in Q2 2024, driven by key drugs Qelbree and GOCOVRI.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.